Navigation Links
Vulnerability to Anthrax Varies Widely: Study
Date:2/6/2012

MONDAY, Feb. 6 (HealthDay News) -- People's susceptibility to anthrax toxin is determined by their genes and can vary greatly among individuals, a new study says.

Anthrax is an infectious disease widely regarded as a potential bioterrorism weapon.

Stanford University School of Medicine researchers analyzed immune cells from 234 people and found that the cells of three of the people were virtually insensitive to anthrax toxin, while the cells of others were hundreds of times more sensitive than those of other people.

The findings could help lead to new treatments and could also have important implications for U.S. national security, according to a university news release. For example, people known to be more resistant could act as first-line responders in an anthrax bioterrorism attack.

The study appears online Feb. 6 in the journal Proceedings of the National Academy of Sciences.

"This research offers an important proof of principle. They've showed that genetically determined variations in the level of expression of a human protein can influence the susceptibility of host cells to anthrax toxin," Dr. David Relman said in the release.

Relman is a professor of microbiology and immunology and of medicine at Stanford, chair of the Institute of Medicine's Forum on Microbial Threats and a member of the U.S. Department of Health and Human Service's National Science Advisory Board for Biosecurity. He was not involved in the study.

"The findings also provide a possible means for predicting who is likely to become seriously ill after exposure, which could be extremely useful when faced with a large number of exposed people, such as was the case during the 2001 anthrax attacks," Relman said. (A week after the 9/11 attacks, letters carrying anthrax spores were mailed within the United States, killing five people and infecting 17 others.)

"Finally, they could lead to the development of novel trea
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Signaling pathways point to vulnerability in breast cancer stem cells
2. PTSD: The serotonin system influences vulnerability and treatment
3. Anthrax Vaccine Shows Promise in Monkeys
4. Anthrax capsule vaccine protects monkeys from lethal infection
5. Natural killer cells could be key to anthrax defense
6. Community storage of anthrax-preventing antibiotics should be determined by state
7. Bacillus anthracis and Anthrax
8. Poll: Hypothetical anthrax attack and antibiotics
9. Rate of follow-up surgeries after partial mastectomy varies greatly
10. Treatment of rectal cancer varies enormously between different European countries
11. Thyroid cancer treatment varies by hospital, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vulnerability to Anthrax Varies Widely: Study
(Date:5/23/2013)... This news release is available in French . ... Montreal researchers have discovered a novel molecular mechanism that ... other diseases of abnormal growth. In the May 23 ... from the University of Montreal explain how they found ... or prevents cells from dividing. , "Cells normally monitor ...
(Date:5/23/2013)... Six innovative research projects have been awarded grants ... the nation's largest private nonprofit funder of Lyme disease medical ... epidemiology of, and treatment and cure for Lyme and ... support the innovative research being conducted by some of ... the field today,” said Harriet Kotsoris, MD, LRA’s Chief ...
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Applied ... solutions, announced today that it has added support for ... IDE, the eiConsole for Healthcare. In addition to ... such as LLP, FTP, and Web Services, it now ... The Direct Protocol is a specification of the ...
(Date:5/23/2013)... During pregnancy both the health of ... medical treatments, especially medication. In July 2006, a ... prompted the FDA to warn about a potential link ... as persistent pulmonary hypertension and other malformations (i). ... (SSRI) drugs. SSRI antidepressants are widely prescribed to ...
(Date:5/23/2013)... Each month Dwell magazine is filled ... and electric cars. Nowhere in America are these pages more ... car capital. Thankfully this June, Green Car Journal is bringing ... to Dwell on Design 2013 ( http://www.dwellondesign.com ), ... two days of Dwell on Design, June 21-22, attendees and ...
Breaking Medicine News(10 mins):Health News:Scientists discover how rapamycin slows cell growth 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5
... ,Time is Brain, SEATTLE, Nov. 14 On ... to activate an advanced telemedicine system,in the emergency rooms ... real-time, 24/7 link between ER physicians and stroke specialists ... Stroke,Program is based. The Swedish TeleStroke Program is ...
... Pa., Nov. 14 Escalon Medical Corp.,(Nasdaq: ESMC ... ended,September 30, 2007. For the first quarter of ... 4% decrease from the $7,168,160, reported in the prior,year ... at the,Company,s Sonomed and Vascular business units, which decreased ...
... Passion for Healthcare, MIAMI, Nov. 14 ... healthcare providers funded by,MTS Health Investors and Oaktree ... E. Burke III to the position of President ... experience to Novis,Pharmaceuticals, with extensive functional expertise in ...
... for November 20, NAPA, Calif., Nov. 14 ... company engaged in the,study of senescense, the science of ... today announced financial results for the,quarter ended September 30, ... $469,000 compared to,$2,027,000 for the same period in the ...
... - Now Families Can Breathe Easier During Cold and ... Nature,s Baby Organics,manufacturers of the finest and purest natural ... Ah-Choo! Chest Rub. Ah-Choo! Chest Rub was,created to bring ... common cold viruses and influenza. "With the unavoidable ...
... NEW YORK, NY November 14, 2007 The ... announced today that they are joining together to create ... of research into drugs and therapies to cure diabetes ... can measure the progress of disease and the effectiveness ...
Cached Medicine News:Health News:Lifesaving TeleStroke Technology Linked to Swedish 2Health News:Lifesaving TeleStroke Technology Linked to Swedish 3Health News:Lifesaving TeleStroke Technology Linked to Swedish 4Health News:Lifesaving TeleStroke Technology Linked to Swedish 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 2Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 2Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 3
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... May 23, 2013  Omeros Corporation (NASDAQ: ... New Drug Application (IND) to evaluate OMS824 in ... Food and Drug Administration (FDA). OMS824 selectively inhibits ... of the brain linked to a wide range ... and schizophrenia. OMS824 has shown promising results in ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... Nov. 14, 2011 Regado Biosciences, Inc., a privately ... with active control agents, announces one poster presentation ... Association (AHA) Scientific Sessions meeting on November 14, ... EST session.  All three presentations highlight results from ...
... Corporation ("the Company"), a leading international manufacturer, marketer, and ... today announced its 2011 third quarter financial results. ... For the third quarter of 2011, the ... of 7.8% versus net sales of $223.7 million in ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4Pregis Announces Third Quarter 2011 Financial Results 2Pregis Announces Third Quarter 2011 Financial Results 3Pregis Announces Third Quarter 2011 Financial Results 4Pregis Announces Third Quarter 2011 Financial Results 5Pregis Announces Third Quarter 2011 Financial Results 6Pregis Announces Third Quarter 2011 Financial Results 7Pregis Announces Third Quarter 2011 Financial Results 8Pregis Announces Third Quarter 2011 Financial Results 9Pregis Announces Third Quarter 2011 Financial Results 10Pregis Announces Third Quarter 2011 Financial Results 11Pregis Announces Third Quarter 2011 Financial Results 12
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: